Clinical Trial: Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)

U.S., July 18 -- ClinicalTrials.gov registry received information related to the study (NCT07712588) titled 'Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)' on July 14.

Brief Summary: This study will treat patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). It will assess the anti-tumor efficacy and safety of birelentinib plus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) vs placebo plus R-CHOP.

Study Start Date: Sept., 2027

Study Type: INTERVENTIONAL

Condition: Diffuse Large B-Cell Lymphoma (DLBCL)

Intervention: DRUG: Birelentinib

Specified dose on specified days

DRUG: Rituximab

Specified dose on specified days

DRUG: Cyclophos...